Nektar Therapeutics and Cellular Biomedicine Group to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced NSCLC
“Early results have shown that NKTR-255 has the potential to emerge as a valuable adjuvant therapy for a range of cell therapy platforms,” said Mary Tagliaferri, M.D., Chief Medical Officer at Nektar Therapeutics. “We are excited to partner with CBMG, a leader in the development of the next generation of cell therapies, to evaluate this novel combination in the clinical setting of lung cancer. Combining NKTR-255 and C-TIL051 could have the potential to deliver deep and durable objective responses with a well-tolerated regimen to patients battling relapsed or refractory NSCLC.”
Share:
More News
“KEYTRUDA has helped transform the treatment of certain cancers, and we continue to pursue innovations that build on this breakthrough medicine to give patients and those who treat them better experiences,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “If approved,
“We are disappointed for ovarian cancer patients desperately lacking new treatment options. There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. We are still on track to
“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We deeply appreciate the patients and investigators who participated in the trial, and we look
“We are grateful for the ongoing guidance and support from the FDA and are very pleased that the agency is fully aligned on our plans related to the Phase 3 trial,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The Phase 2 OVATION 2 study data are
